Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort

Journal of Crohn's and Colitis

Volumn 8, Issue 10, 2014, Pages 1217-1221

  Orlando, Ambrogio ^a   Mocciaro, Filippo ^b   Renna, Sara ^a   Scimeca, Daniela ^c   Rispo, Antonio ^d   Lia Scribano, Maria ^e   Testa, Anna ^d   Aratari, Annalisa ^f   Bossa, Fabrizio ^c   Tambasco, Rosy ^g   Angelucci, Erika ^h   Onali, Sara ⁱ   Cappello, Maria ^j   Fries, Walter ^k   D'Incà, Renata ^l   Martinato, Matteo ^l   Castiglione, Fabiana ^d   Papi, Claudio ^f   Annese, Vito ^m   Gionchetti, Paolo ^g   Rizzello, Fernando ^g   Vernia, Piero ^h   Biancone, Livia ⁱ   Kohn, Anna ^e   Cottone, Mario ^a   more..

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b Gastroenterology Unit   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Stroke Unit   (Italy)

^f SAN FILIPPO NERI HOSPITAL   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j UNIVERSITY OF PALERMO   (Italy)

^k UNIVERSITY OF MESSINA   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

5 Aminosalicylic acid; Crohn's disease; Endoscopic recurrence; Severe recurrence

Indexed keywords

AZATHIOPRINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; ASSOCIATION; COLON DISEASE; COLONOSCOPY; CROHN DISEASE; DISEASE SEVERITY; EARLY INTERVENTION; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; ITALY; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; SEVERITY OF ILLNESS INDEX; TIME; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; ITALY; MALE; MESALAMINE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84908256578     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.02.010     Document Type: Article

References (24)

1. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30:699-706.
2. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
3. Rutgeerts P., Geboes K., Vantrappen G., Kerremans R., Coenegrachts J.L., Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984, 25:665-672.
4. Malchow H., Scheurlen M., Hotz T., Daiss W. The early signs of Crohn's disease after surgery - a prospective trial. Gastrointest Endosc 1987, 33:163.
5. Doherty G., Bennett G., Patil S., Cheifetz A., Moss A.C. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009, 4:CD006873.
6. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
7. Sorrentino D., Terrosu G., Avellini C., Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007, 167:1804-1807.
8. Yoshida K., Fukunaga K., Ikeuchi H., Kamikozuru K., Hida N., Ohda Y., et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012, 18:1617-1623.
9. Yamamoto T., Umegae S., Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009, 15:1460-1466.
10. Fernandez-Blanco I., Monturiol J., Martinez B. Adalimumab in the prevention of postoperative recurrence of Crohn's disease. Gastroenterology 2010, 138.
11. Papamichael K., Archavlis E., Lariou C., Mantzaris G.J. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis 2012, 6:924-931.
12. Savarino E., Bodini G., Dulbecco P., Assandri L., Bruzzone L., Mazza F., et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013, 108:1731-1742.
13. Cammà C., Giunta M., Rosselli M., Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997, 113:1465-1473.
14. Reinisch W., Angelberger S., Petritsch W., Shonova O., Lukas M., Bar-Meir S., et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
15. Orlando A., Armuzzi A., Papi C., Annese V., Ardizzone S., Biancone L., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011, 43:1-20.
16. Van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010, 4:63-101.
17. De Cruz P., Kamm M.A., Prideaux L., Allen P.B., Desmond P.V. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012, 18:758-777.
18. Renna S., Cammà C., Modesto I., Cabibbo G., Scimeca D., Civitavecchia G., et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008, 135:1500-1509.
19. Florent C., Cortot A., Quandale P., Sahmound T., Modigliani R., Sarfaty E., et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 1996, 8:229-233.
20. Brignola C., Cottone M., Pera A., Ardizzone S., Scribano M.L., De Franchis R., et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995, 108:345-349.
21. McLeod R.S., Wolff B.G., Steinhart A.H., Carryer P.W., O'Rourke K., Andrews D.F., et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995, 109:404-413.
22. Lochs H., Mayer M., Fleig W.E., Mortensen P.B., Bauer P., Genser D., et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000, 118:264-273.
23. Hanauer S.B., Korelitz B.I., Rutgeerts P., Peppercorn M.A., Thisted R.A., Cohen R.D., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
24. Caprilli R., Cottone M., Tonelli F., Sturniolo G., Castiglione F., Annese V., et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003, 17:517-523.